The alphavirus replicon technology has been utilized for many years to develop vaccines for both veterinary and human applications. Many developments have been made to the replicon platform recently, resulting in improved safety and efficacy of replicon particle (RP) vaccines. This review provides a broad overview of the replicon technology and safety features of the system and discusses the current literature on RP and replicon-based vaccines.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1017/S1466252312000011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oncolytic alphavirus-induced extracellular vesicles counteract the immunosuppressive effect of melanoma-derived extracellular vesicles.
Sci Rep
January 2025
Center for Translational Research in Oncology (LIM/24), Instituto do Cancer do Estado de Sao Paulo, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, CEP 01246-000, Brazil.
Extracellular vesicles (EVs)-mediated communication by cancer cells contributes towards the pro-tumoral reprogramming of the tumor microenvironment. Viral infection has been observed to alter the biogenesis and cargo of EVs secreted from host cells in the context of infectious biology. However, the impact of oncolytic viruses on the cargo and function of EVs released by cancer cells remains unknown.
View Article and Find Full Text PDFSelf-Replicating Alphaviruses: From Pathogens to Therapeutic Agents.
Viruses
November 2024
PanTherapeutics, CH1095 Lutry, Switzerland.
Alphaviruses are known for being model viruses for studying cellular functions related to viral infections but also for causing epidemics in different parts of the world. More recently, alphavirus-based expression systems have demonstrated efficacy as vaccines against infectious diseases and as therapeutic applications for different cancers. Point mutations in the non-structural alphaviral replicase genes have generated enhanced transgene expression and created temperature-sensitive expression vectors.
View Article and Find Full Text PDFFacile quantitative diagnostic testing for neutralizing antibodies against Chikungunya virus.
BMC Infect Dis
September 2024
Institute of Preventive Medicine, National Defense Medical Center, 237010 No. 172, Dapu Rd., Sanxia Dist, Taipei, 11490, Taiwan.
Article Synopsis
- Viral neutralization assays are important for evaluating immune responses and the effectiveness of vaccines or monoclonal antibodies, but traditional methods like FRNT require high-cost, biosafety level 3 facilities, limiting their use, especially for studying chikungunya virus (CHIKV).
- The study tested a safer surrogate virus neutralization test (sVNT) using CHIKV replicon particles (VRPs) that allows rapid detection and quantification of neutralizing antibodies in human serum, showing promising results.
- sVNT achieved 100% sensitivity and specificity in screening, with a strong correlation (Pearson's r = 0.83) with the traditional FRNT method, making it a reliable alternative for assessing neutralizing activity
First Experimental Application of DNA-Layered Salmonid Alphavirus-Based Replicon Vaccine in Non-Salmonid Fish: Induced Early Semi-Specific Protection against Spring Viraemia of Carp Virus (SVCV) in Common Carp ().
Animals (Basel)
September 2024
HUN-REN Veterinary Medical Research Institute, H-1143 Budapest, Hungary.
Our study demonstrates the first application of the salmonid alphavirus-based replicon vector system (pSAV) as a DNA vaccine in a non-salmonid fish species, in common carp () against spring viraemia of carp virus (SVCV). SAV replicon encoding the glycoprotein of the SVCV was used as a DNA-layered plasmid, and its efficacy was compared with a previously described conventional DNA vaccine construct (pcDNA3.1 based vector) and with a control group (pcDNA3.
View Article and Find Full Text PDFPackaging of alphavirus-based self-amplifying mRNA yields replication-competent virus through a mechanism of aberrant homologous RNA recombination.
mBio
October 2024
Wageningen University and Research, Laboratory of Virology, Wageningen, the Netherlands.
Messenger (m)RNA has taken center stage in vaccine development, gene therapy, and cancer immunotherapy. A next-generation of mRNA is the self-amplifying (sa)mRNA, which induces broad and long-lasting immunity at a lower dose which provides better clinical outcomes in conjunction with fewer adverse effects. SamRNA, also known as "replicon" RNA, encodes the replication machinery of an alphavirus together with an antigen.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!